Aquestive Therapeutics Inc Cash Flow-to-Debt Ratio
Aquestive Therapeutics Inc cash flow-to-debt ratio. Aquestive Therapeutics Inc (AQST) has a Cash Flow-to-Debt Ratio of -0.08x as of March 2026, meaning its operating cash flow of $-14.81 Million could theoretically repay 0% of its total liabilities ($175.18 Million) in one year. Check AQST operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aquestive Therapeutics Inc (2005–2025)
Cash flow-to-debt ratio of Aquestive Therapeutics Inc from 2005 to 2025. Historical debt coverage capacity for Aquestive Therapeutics Inc across 12 annual periods. Check Aquestive Therapeutics Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Aquestive Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2005–2025)
Aquestive Therapeutics Inc cash flow-to-debt ratio by year from 2005 to 2025. Year-by-year debt coverage analysis for Aquestive Therapeutics Inc. For the full cash flow conversion analysis, see AQST cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.27x | $-52.43 Million | $194.09 Million | ▼ -22.1% |
| 2024 | -0.22x | $-35.76 Million | $161.58 Million | ▼ -468.6% |
| 2023 | -0.04x | $-6.38 Million | $163.91 Million | ▲ +30.2% |
| 2022 | -0.06x | $-9.79 Million | $175.62 Million | ▲ +75.6% |
| 2021 | -0.23x | $-32.98 Million | $144.13 Million | ▲ +43.9% |
| 2020 | -0.41x | $-45.46 Million | $111.38 Million | ▲ +42.7% |
| 2019 | -0.71x | $-60.21 Million | $84.60 Million | ▼ -320.6% |
| 2018 | -0.17x | $-12.99 Million | $76.77 Million | ▼ -302.3% |
| 2017 | 0.08x | $5.82 Million | $69.61 Million | ▲ +158.3% |
| 2016 | -0.14x | $-8.18 Million | $56.97 Million | ▲ +97.0% |
| 2006 | -4.83x | $-9.26 Million | $1.92 Million | ▼ -477.2% |
| 2005 | -0.84x | $-6.39 Million | $7.64 Million | — |